ALB and small cell lung carcinoma: The combination of CBP with Abraxane (Nanoparticle Albumin-Bound Paclitaxel) to treat small cell lung cancer significantly improved the efficacy, reduced the dosing frequency, and removed the requirement for weekly therapy as it showed anticancer activity in patients when it was given every 3 weeks [123].